Pfizer Nears Pre-Pandemic Levels: Is the Stock Ready to Bottom Out?

Given the company’s strong cash position, we expect a potential special dividend payout in the near future.

Pfizer - Expect A Fresh Wave Of New Launches: Systematix Initiates Coverage With A ‘Buy’

JB Chemicals & Pharmaceuticals on Wednesday received approval from the US health regulator to market a generic product, used to treat mood disorders, in the American market. The company’s product is the generic version of Pfizer’s Sinequan capsules which are indicated for the treatment of anxiety, d…

JB Chemicals gets USFDA nod to market generic medication

Brigade Enterprises acquires 6.54-acre land parcel in Chennai from Pfizer Healthcare India for ₹139 crore. Plans to develop a residential project in this space. 50% of 10 million sq ft sales to come from Chennai and Hyderabad markets. Shares of Brigade Enterprises closed flat at ₹589.40 on NSE.

Brigade Enterprises acquires 6.54 acres in Chennai from Pfizer Healthcare for ₹139 cr

In a regulatory filing on Tuesday, Brigade Enterprises said “6.54 acres of land parcel...was acquired from Pfizer Healthcare India Pvt Ltd for an overall consideration of Rs 138.83.” “We will be developing a residential project on this land parcel with an overall development of over one million squa…

Brigade Enterprises acquires 6.54-acre land parcel in Chennai from Pfizer at Rs 139 crore

The Pfizer shot, which was already approved for use in older adults, has now been greenlighted for use as a single injection from 32 through 36 weeks of pregnancy, to protect infants from birth through six months, a statement by the Food and Drug Administration said.

US approves maternal vaccine to prevent RSV in infants

Moderna and other COVID-19 vaccine makers Novavax, Pfizer and German partner BioNTech SE have created versions of their shots aimed at the XBB.1.5 subvariant.

Moderna’s updated COVID vaccine effective against ‘Eris’ variant in humans

Among pharmaceutical heavyweights, Pfizer edged lower in choppy trading after the drugmaker’s quarterly revenue fell short of Wall Street expectations, hit by declining sales of its COVID-19 products.

US stock market: S&P 500, Nasdaq end lower on first day of August in busy earnings week

Pfizer trims 2023 revenue outlook as profits tumble

Among pharmaceutical heavyweights, Pfizer edged lower in choppy trading after the drugmaker fell short of Wall Street expectations for quarterly revenue, hit by declining sales of its COVID-19 products.

Wall St falls after mixed earnings, downbeat manufacturing data

1 Stock to Buy, 1 Stock to Sell This Week: Apple, Pfizer

Hasn't fared well - amongst the low performers

Performance

Seems to be overvalued vs the market average

Valuation

Lagging behind the market in financials growth

Growth

Showing good signs of profitability & efficiency

Profitability

The stock is overpriced but is not in the overbought zone

Current price is more than the intrinsic value

Fundamentals

Good time to consider, stock is not in the overbought zone

Technicals

Entry point

Promoter pledged holding

Unsolicited messages

Default probability

Red flags

Pfizer Limited is a pharmaceutical company. The Company has a portfolio of approximately 140 products across over 15 therapeutic areas.

Pfizer Ltd